How Does Tirzepatide Work?

Tirzepatide is the newest class of injectable weight loss medication — and it's producing results that have genuinely surprised the medical community. In clinical trials, patients lost an average of 20–22% of their body weight, making it the most effective pharmacological weight loss treatment ever studied.

The Science: What Makes Tirzepatide Different

Semaglutide mimics GLP-1 only. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual action is what sets it apart.

What GLP-1 Activation Does

• Slows gastric emptying
• Signals the brain to reduce hunger and increase satiety
• Stimulates insulin release in response to meals
• Suppresses glucagon

What GIP Activation Adds

• Further enhances insulin secretion after meals
• Works synergistically with GLP-1 to amplify appetite suppression
• May have favorable effects on fat distribution and energy metabolism

Brand Names: Mounjaro vs Zepbound

Tirzepatide is the same molecule in both brand names — the difference is the FDA-approved indication:

• Mounjaro — FDA-approved in 2022 for type 2 diabetes management
• Zepbound — FDA-approved in 2023 for chronic weight management

Dosing and Titration Schedule

Standard Zepbound titration schedule:

• Weeks 1–4: 2.5 mg weekly
• Weeks 5–8: 5 mg weekly
• Weeks 9–12: 7.5 mg weekly
• Weeks 13–16: 10 mg weekly
• Weeks 17–20: 12.5 mg weekly
• Week 21+: 15 mg weekly (maximum dose)

If using compounded tirzepatide, see our tirzepatide reconstitution guide for mixing instructions, and use our dose calculator to convert your dose to syringe units.

What Results Can You Expect?

The SURMOUNT-1 clinical trial showed average weight loss of 20.9% at the 15 mg dose over 72 weeks — significantly greater than semaglutide's ~15% average.

• Weeks 1–4: Appetite begins to decrease. Some nausea. Minimal weight change.
• Month 2–3: Noticeable appetite suppression. Weight loss accelerates.
• Month 3–6: Significant weight loss at 7.5–10 mg doses.
• Month 6–12: Continued weight loss, plateau common.

Tirzepatide vs Semaglutide

• Weight loss: Tirzepatide wins — ~20% vs ~15% average
• Cardiovascular data: Semaglutide currently has stronger published CV outcome data
• Insurance coverage: Semaglutide currently has broader coverage pathways
• Side effects: Broadly similar GI profiles

For a full comparison see our Tirzepatide vs Semaglutide guide.

Common Side Effects of Tirzepatide

• Nausea — most common, particularly after dose increases
• Diarrhea — affects a significant percentage early in treatment
• Constipation — alternates with diarrhea in some patients
• Fatigue — common early, typically improves

For a complete guide see our GLP-1 Side Effects guide.